Pediatric Promise: China Bets On Better Medicines Amid Three Child Policy Roll-Out
But Industry Incentives Still Limited
Executive Summary
As China's regulators renew moves to encourage the development of pediatric medicines, indication expansion may give health players a new growth engine, despite remaining policy challenges and lingering market uncertainties.
You may also be interested in...
Catch-22: Biotech Boom Brings Clinical Services, Regulatory Crunch In China
China’s booming biotech sector shows no signs of slowing and is spurring many contract clinical and manufacturing service providers to double their bets in a market that remains largely untapped for innovative biologics. But whether the boom will turn to a bubble remains to be seen.
No OS Gain For 34 China-Approved Cancer Drug Indications
Sweeping regulatory reforms put China in catch-up mode for the approval of oncology drugs, some of which have been cleared for marketing only in the country. But how does the deluge of new products measure up in terms of actual overall survival benefits? A new study by Peking University scholars and specialists unveils some surprising results.
Chinese-Language Podcast: 聊聊七月生物制药热门话题
Join our China-based content team for this latest Chinese-language podcast episode discussing selected hot topics impacting the biopharma industry in China, including a homegrown COVID-19 antiviral approval, ADC deals and cross-strait tensions and their impact on the biotech sector.